

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Claim 1. (Currently Amended) A ~~recombinant replication-defective~~ chimpanzee ~~adenoviral~~ vector comprising a sequence of nucleotides derived from SEQ ID NO: 1, wherein the vector has a functional deletion of the E1 gene in which is at least partially deleted in E1 and devoid of E1 activity comprising the sequence of nucleotides as set forth in SEQ ID NO: 1 ~~and lacks E1 activity~~.

Claims 2-5. (Canceled)

Claim 6. (Currently Amended) The ~~recombinant replication-defective~~ ChAd vector of claim 1 which comprises a deletion/disruption in the E1 nucleotide sequence in the region from bp 460 to bp 3542 of SEQ ID NO: 1.

Claim 7. (Canceled)

Claim 8. (Currently Amended) The ~~recombinant replication-defective~~ ChAd vector according to claim 6 wherein the vector further comprises a transgene encoding at least one tumor associated antigen (TAA) operatively linked to a promoter capable of directing expression of the transgene.

Claim 9-43. (Canceled)

Claim 44 (Currently Amended) An isolated host cell comprising the recombinant adenoviral vector of claim 1 ~~43~~.

Claim 45 (Currently Amended) A method for producing recombinant, ~~replication-defective~~ chimpanzee adenovirus particles comprising:
(a) transfecting a recombinant adenoviral vector of claim 1 into a population of cells; and
(b) harvesting the resulting recombinant, ~~replication-defective~~ adenovirus.

Claim 46 (Currently Amended) The recombinant ChAd vector of claim 1 43, further comprising a transgene encoding heterologous nucleic acid which encodes at least one immunogen operatively linked to regulatory sequences which direct expression of said transgene heterologous nucleic acid in mammalian cells.

Claim 47 (Canceled)

Claim 48 (Currently Amended) The recombinant ChAd vector of claim 1 43, wherein the vector further comprises at least a partial deletion of nucleotide sequences which encode the adenovirus E3 protein.

Claim 49 (Currently Amended) The recombinant ChAd vector of claim 1 [[43,]], wherein the vector is completely deleted in E1.

Claim 50 (Currently Amended) The isolated host cell of claim 44, wherein the host cell is a 293 cell or a ~~PER.C6™~~ cell as deposited with the ECACC under accession number 96022940 and wherein the cell propagates the recombinant adenoviral vector.

Claim 51 (New) The recombinant chimpanzee adenoviral vector according to claim 8 wherein the at least one TAA is selected from the group consisting of: HER2/Neu, CEA, EpCAM, PSA, PSMA, Telomerase, gp100, Melan-A/MART-1, Muc-1, NY-ESO-1, Survivin, Stromelysin 3, Tyrosinase, MAGE3, CML68, CML66, OY-TES-1, SSX-2, SART-1, SART-2, SART-3, NY-CO-58, NY-BR-62, hKLP2, 5T4 AND VEGFR2.

Claim 52. (New) The recombinant chimpanzee adenoviral vector according to claim 46 wherein the transgene is derived from an infectious agent selected from the group consisting of: HIV, HBV, HCV, HPV, HSV1, HSV2, SARS COV, Plasmodium malariae, Ebola Virus, West Nile Virus, Dengue Virus, Influenza A, Influenza B, Mycobacterium tuberculosis, Cytomegalovirus, respiratory syncytial virus, and Leishmania major.